ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens
YONKERS, N.Y., April 20, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
The $2 Trillion Valuation Debate Skips What Anthropic Knows
Pharmacore secures funding to improve medication regimen reviews in long-term care